{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:52:27Z","timestamp":1781830347849,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the indications and real-world treatment outcomes of intravitreal bevacizumab in a resource-limited community eye hospital setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included patients who received IVB injection at Hetauda Community Eye Hospital between January 2019 and December 2022. Inclusion criteria:\n                      <jats:inline-formula>\n                        <jats:tex-math>$$\\:\\ge\\:$$<\/jats:tex-math>\n                      <\/jats:inline-formula>\n                      1 IVB injection; retinal diagnosis confirmed clinically and by Optical Coherence Tomography (OCT) where available. Exclusion criteria: missing baseline Visual Acuity (VA) or OCT,\n                      <jats:inline-formula>\n                        <jats:tex-math>$$\\:&lt;1$$<\/jats:tex-math>\n                      <\/jats:inline-formula>\n                      month follow-up. Median visual acuity (VA) and central macular thickness (CMT) changes were compared using Wilcoxon signed\u2011rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 418 injections were administered to 247 patients (260 eyes). After excluding those lost to follow\u2011up, 221 patients (234 eyes) were included in the analysis. Median baseline CMT was 366\u00a0\u03bcm and improved to 236\u00a0\u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Most patients received one injection (57%) followed by two injections (30%). The median baseline VA was 0.78 log MAR and remained 0.78 log MAR overall (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.108), but subgroup improvements were significant in DME, nAMD, BRVO, and central retinal vein occlusion (CRVO).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IVB resulted in significant anatomical and functional improvements in patients with retinal diseases. The findings reflect real\u2011world outcomes in a community\u2011level eye hospital, where cost barriers limit repeated injections. The limitations of this study include its retrospective design, variable follow\u2011up, absence of control group, and limited numbers of injections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-05039-6","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:59:50Z","timestamp":1781780390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indications and outcome of intravitreal bevacizumab injection in a Community Eye Hospital, Nepal"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-819X","authenticated-orcid":false,"given":"Sunil","family":"Thakali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Gauchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hom Bahadur","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"6","key":"5039_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4103\/0301-4738.36474","volume":"55","author":"FZ Salvatore Grisanti","year":"2007","unstructured":"Salvatore Grisanti FZ. Bevacizumab: Off -label use in ophthalmology. Indian J Ophthalmol. 2007;55(6):417\u201320.","journal-title":"Indian J Ophthalmol"},{"key":"5039_CR2","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"SPH Usha Chakravarthy","year":"2013","unstructured":"Usha Chakravarthy SPH, Chris A, Rogers SM, Downes AJ, Lotery LA, Culliford, Barnaby C. Reeves, on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year fi ndings of the IVAN randomised controlled trial. Lancet. 2013;382:1258\u201367.","journal-title":"Lancet"},{"issue":"5","key":"5039_CR3","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.4103\/ijo.IJO_1748_22","volume":"71","author":"SKG Ruchi Agarwal","year":"2023","unstructured":"Ruchi Agarwal SKG, Siddharth Agrawal. Efficacy and safety analysis of intravitreal bio-similar products of bevacizumab in patients with macular edema because of retinal diseases. Indian J Ophthalmol. 2023;71(5):2066\u201370.","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"5039_CR4","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.ophtha.2013.02.002","volume":"120","author":"JD Stein","year":"2013","unstructured":"Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120(9):1835\u201342.","journal-title":"Ophthalmology"},{"issue":"3","key":"5039_CR5","first-page":"1093","volume":"17","author":"ASS Mehrdad Afarid","year":"2018","unstructured":"Mehrdad Afarid ASS, Feisal Rahat and Ali Azimi. Intravitreal Injection of Bevacizumab: Review of our previous Experience. Iran J Pharm Res. 2018;17(3):1093\u20138.","journal-title":"Iran J Pharm Res"},{"key":"5039_CR6","doi-asserted-by":"crossref","unstructured":"Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, Wu L, for the Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema. Ophthalmology. 2009(116):1481\u20137.","DOI":"10.1016\/j.ophtha.2009.04.006"},{"key":"5039_CR7","first-page":"2109","volume":"14","author":"SK Raba Thapa","year":"2020","unstructured":"Raba Thapa SK. Hendra Stevie Tan,Suman Shumsher Thapa, Gerardus Hermanus Maria Bartholomeus van Rens. Prevalence, Pattern and Risk Factors of Retinal Diseases Among an Elderly Population in Nepal: The Bhaktapur Retina Study. Clin Ophthalmol. 2020;14:2109\u201318.","journal-title":"Clin Ophthalmol"},{"key":"5039_CR8","unstructured":"Rapid assessment of avoidable blindness survey. The epidemiology of blindness in Nepal. Nepal Netra Jyoti Sangh. 2012."},{"issue":"5","key":"5039_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.5301\/ejo.5000118","volume":"22","author":"P Sofija","year":"2012","unstructured":"Sofija P, Davidovi\u0107 SVN, Nikola J, \u0106uri\u0107, Dragan O, Dra\u0161kovi\u0107 VS, \u010cabarkapa, Slobodanka LJ, Latinovi\u0107. Zoran Z. Sto\u0161i\u0107. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol. 2012;22(5):792\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"5039_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.18502\/jovr.v16i2.9092","volume":"16","author":"B Bradley Beatson","year":"2021","unstructured":"Bradley Beatson B. Fernando Arevalo. From the Hypotheses to Clinical Evidence in Retinal Therapy. J Ophthalmic Vis Res. 2021;16(2):287\u201390.","journal-title":"J Ophthalmic Vis Res"},{"key":"5039_CR11","doi-asserted-by":"crossref","unstructured":"Wirkkala J, Bloigu R, Hautala NM. Intravitreal bevacizumab improves the clearance of vitreous haemorrhage and visual outcomes in patients with proliferative diabetic retinopathy. BMJ Open Ophth. 2019;4.","DOI":"10.1136\/bmjophth-2019-000390"},{"key":"5039_CR12","doi-asserted-by":"crossref","unstructured":"Kornhauser T, Schwartz R, Goldstein M, Neudorfer M, Loewenstein A, Barak A. Bevacizumab treatment ofmacular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol. 2015.","DOI":"10.1007\/s00417-015-3130-z"},{"issue":"3","key":"5039_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.18502\/jovr.v14i3.4791","volume":"14","author":"HR-E Alireza Lashay","year":"2019","unstructured":"Alireza Lashay HR-E, Mirghorbani M. Mehdi Yaseri. Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2019;14(3):336\u201365.","journal-title":"J Ophthalmic Vis Res"},{"issue":"2","key":"5039_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/02713680903428306","volume":"35","author":"EY Ozgur Artunay","year":"2010","unstructured":"Ozgur Artunay EY, Rasier R, Sengul A, Bahcecioglu H. Intravitreal Bevacizumab in Treatment of Idiopathic Persistent Central Serous Chorioretinopathy: A Prospective, Controlled Clinical Study. Curr Eye Res. 2010;35(2):91\u20138.","journal-title":"Curr Eye Res"},{"key":"5039_CR15","doi-asserted-by":"crossref","unstructured":"Shrestha R, Karki P, Joshi SN. Outcome of intravitreal bevacizumab injection without pre and postoperative antibiotics. BMC Ophthalmol. 2020;20(145).","DOI":"10.1186\/s12886-020-01420-1"},{"issue":"8","key":"5039_CR16","first-page":"37","volume":"4","author":"ES Babita Gurung","year":"2021","unstructured":"Babita Gurung ES, Hara M, Gurung HB, Adhikari. Anju Gurung, Krishna Gurung and Pawan Baral. Intravitreal Injection Bevacizumab: Main Indications. Acta Sci Ophthalmol. 2021;4(8):37\u20139.","journal-title":"Acta Sci Ophthalmol"},{"issue":"15","key":"5039_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3126\/nepjoph.v8i1.16157","volume":"8","author":"RT Shyam Vyas","year":"2016","unstructured":"Shyam Vyas RT, Sanyam Bajimaya E, Pradhan S, Bhandari G, Paudyal. Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema. Nepal J Ophthalmol. 2016;8(15):54\u201361.","journal-title":"Nepal J Ophthalmol"},{"issue":"24","key":"5039_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3126\/nepjoph.v12i2.28959","volume":"24","author":"PJ Pawan Mahat","year":"2020","unstructured":"Pawan Mahat PJ. Eli Pradhan,Prabha Subedi. Evaluation of the Effect of Intravitreal Bevacizumab (Avastin) in Patients with Diabetic Macular Edema. Nepal J Ophthalmol. 2020;24(24):236\u201344.","journal-title":"Nepal J Ophthalmol"},{"key":"5039_CR19","doi-asserted-by":"crossref","unstructured":"Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120(9):1835\u201342.","DOI":"10.1016\/j.ophtha.2013.02.002"},{"issue":"2","key":"5039_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40123-023-00672-6","volume":"12","author":"OA Sam-Oyerinde","year":"2023","unstructured":"Sam-Oyerinde OA, Patel PJ. Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low\/Lower-Middle-Income Countries. Ophthalmol Ther. 2023;12(2):809\u201326.","journal-title":"Ophthalmol Ther"},{"key":"5039_CR21","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.2147\/OPTH.S317771","volume":"15","author":"S Pramanik","year":"2021","unstructured":"Pramanik S, Mondal LK, Paine SK, Jain S, Chowdhury S, Ganguly U, et al. Efficacy and Cost-Effectiveness of Anti-VEGF for Treating Diabetic Retinopathy in the Indian Population. Clin Ophthalmol. 2021;15:3341\u201350.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"5039_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12886-020-01420-1","volume":"20","author":"R Shrestha","year":"2020","unstructured":"Shrestha R, Karki P, Joshi SN. Outcome of intravitreal bevacizumab injection without pre and postoperative antibiotics. BMC Ophthalmol. 2020;20(1):145.","journal-title":"BMC Ophthalmol"},{"key":"5039_CR23","doi-asserted-by":"crossref","unstructured":"Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030. Front Endocrinol. 2023;13\u20132022.","DOI":"10.3389\/fendo.2022.1077669"},{"key":"5039_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4274\/tjo.82542","volume":"46","author":"YY Cengiz Alag\u00f6z","year":"2016","unstructured":"Cengiz Alag\u00f6z YY, Murat Kocamaz \u00d6kke\u015f, Baz U\u011fur, \u00c7i\u00e7ek B, \u00c7elik. Halil \u0130brahim Demirkale, Ahmet Taylan Yaz\u0131c\u0131 MT. The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects. Turk J Ophthalmol. 2016;46:221\u20135.","journal-title":"Turk J Ophthalmol"},{"key":"5039_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41433-022-02006-5","volume":"36","author":"R Rachel","year":"2022","unstructured":"Rachel R, Kabunga JO. Sam Ruvuma and Simon Outcome of intravitreal Avastin injections in patients with macular oedema in Uganda: a cohort study. Eye (Lond). 2022;36:45\u201350.","journal-title":"Eye (Lond)"},{"issue":"2","key":"5039_CR26","first-page":"364","volume":"28","author":"MN Sanaullah Jan","year":"2016","unstructured":"Sanaullah Jan MN, Karim S. Intravitreal Bevacizumab: Indications and Complications. J Ayub Med Coll Abbottabad. 2016;28(2):364\u20138.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"241","key":"5039_CR27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.31729\/jnma.5515","volume":"59","author":"RS Arjun Shrestha","year":"2021","unstructured":"Arjun Shrestha RS, Shrestha R, Suwal B. Use of Intravitreal Bevacizumab Injection among Patients Undergoing Surgical Retinal Interventions at Tertiary Eye Hospital: A Descriptive Cross-sectional Study. J Nepal Med Assoc. 2021;59(241):858\u201361.","journal-title":"J Nepal Med Assoc"},{"key":"5039_CR28","doi-asserted-by":"crossref","unstructured":"Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340(c2459).","DOI":"10.1136\/bmj.c2459"},{"key":"5039_CR29","doi-asserted-by":"crossref","unstructured":"Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology. 2014;121(4).","DOI":"10.1016\/j.ophtha.2013.10.037"},{"key":"5039_CR30","doi-asserted-by":"crossref","unstructured":"Kumluang S, Ingsrisawang L, Sangroongruangsri S, Chaikledkaew U, Ratanapakorn T, Ruamviboonsuk P, Taweebanjongsin W, Choovuthayakorn J, Thoongsuwan S, Hanutsaha P, Kulvichit K. A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand. BMC Ophthalmol. 2019;19(82).","DOI":"10.1186\/s12886-019-1086-1"},{"key":"5039_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12886-017-0578-0","volume":"17","author":"HW Lim","year":"2017","unstructured":"Yong Un Shin\u2020 EHH, Lim HW, Kang MH. Mincheol Seong and Heeyoon Cho. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. BMC Ophthalmol. 2017;17:182.","journal-title":"BMC Ophthalmol"},{"key":"5039_CR32","doi-asserted-by":"crossref","unstructured":"Padhy S, Kumar V. Dramatic response to intravitreal bevacizumab in hypertensive retinopathy. Indian J Ophthalmol. 2022;66(10).","DOI":"10.4103\/ijo.IJO_214_18"},{"key":"5039_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sjopt.2012.02.005","volume":"27","author":"AG Salman","year":"2013","unstructured":"Salman AG. Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension. Saudi J Ophthalmol. 2013;27:25\u20139.","journal-title":"Saudi J Ophthalmol"},{"key":"5039_CR34","doi-asserted-by":"crossref","unstructured":"Akesbi J, Brousseaud FX, Adam R, Rodallec T, Nordmann JP. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis. Acta Opthalmologica. 2010.","DOI":"10.1111\/j.1755-3768.2009.01540.x"},{"key":"5039_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000512300","volume":"64","author":"AT Janejit Choovuthayakorn, Phichayut","year":"2021","unstructured":"Janejit Choovuthayakorn, Phichayut Phinyo AT. Paradee Kunavisarut,Direk Patikulsila, Voraporn Chaikitmongkol, Nawat Watanachai,Kessara Pathanapitoon. Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema in Clinical Practice of Single Center: Three-Year Outcomes. Ophthalmic Res. 2021;64:483\u201393.","journal-title":"Ophthalmic Res"},{"key":"5039_CR36","doi-asserted-by":"crossref","unstructured":"Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, Brito M, Alezzandrini AA, Restrepo N, Berrocal MH, Saravia M. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: The 2010 GLADAOF lecture. J Ophthalmol. 2011;2011.","DOI":"10.1155\/2011\/584238"},{"key":"5039_CR37","doi-asserted-by":"crossref","unstructured":"Ahn SJ, Ahn J, Woo SJ, Park KH. Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion. BioMed Res Int. 2013.","DOI":"10.1155\/2013\/209735"},{"key":"5039_CR38","doi-asserted-by":"crossref","unstructured":"Bhandari S, Poudel M, Paudyal I, Joshi PL, Shrestha C, Paudyal G, Pradhan E. Treatment outcomes of retinal vein occlusion in clinical practice in Nepal. BMC Ophthalmol. 2021;21(92).","DOI":"10.1186\/s12886-021-01857-y"},{"key":"5039_CR39","doi-asserted-by":"crossref","unstructured":"Pikkel J, Chassid O, Busool Y, Srour W, Sharabi-Nov A, Beiran I. Bevacizumab for CRVO associated CME: effect of timing and frequency of injections on final visual outcome. J Ophthalmol. 2013.","DOI":"10.1155\/2013\/974670"},{"issue":"9","key":"5039_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3126\/nepjoph.v5i1.7824","volume":"5","author":"RPG Thapa","year":"2013","unstructured":"Thapa RPG. Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Nepal J Ophthalmol. 2013;5(9):63\u20138.","journal-title":"Nepal J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-05039-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05039-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-05039-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:03:10Z","timestamp":1781827390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-05039-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5039"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-05039-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this retrospective study was obtained from the Institutional Review Board of the Tilganga Institute of Ophthalmology (Reference No. 18\/2023, dated 3 October 2023). The requirement for informed consent to participate was waived by the Institutional Review Board because of the retrospective nature of the study and the use of anonymized patient data. All methods were carried out in accordance with relevant guidelines and regulations, including the principles of the Declaration of Helsinki. Patient confidentiality was strictly maintained throughout the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}